72 results about "Co incubation" patented technology

The invention is composed of monoclonal human MN antibodies or MN antibody fragments that target the GEEDLP (SEQ ID NO: 118) repeat within the proteoglycan domain. The proteoglycan domain of the MN cell surface protein contains four of these identical GEEDLP (SEQ ID NO: 118) repeats. Binding to the desired epitope is verified by competition ELISA, where ELISA signal can be attenuated by co-incubation with a peptide containing this repeat (PGEEDLPGEEDLP (SEQ ID NO: 119)). This inhibition of binding can also be verified using Biacore assays, where binding of desired antibodies to immobilized MN or proteoglycan peptides can be inhibited by the peptide repeat. In addition to binding to the peptide repeat, human anti-MN antibodies can inhibit the cell adhesion of CGL-1 cells to MN coated plastic plates. Human anti-MN antibodies have been used to diagnose and quantify MN expression in cancer cells and tumors using FACS and immunohistochemical methods. An example is also provided where a human anti-MN IgG1 mediates tumor cell lysis though antibody-dependent cell-mediated cytotoxicity. Therefore, these antibodies will be useful for the treatment of cancers in which MN is upregulated or can be useful for the diagnosis of cancers in which MN is upregulated.

The invention relates to the technical field of sewage treatment, and in particular to preparation method of magnetic biochar loaded photosynthetic bacteria material and a sewage treatment method. The preparation method comprises the steps of: preparing a magnetic nano iron oxide material by a chemical coprecipitation method, conducting activation and expansion culture on photosynthetic bacteria, loading the nano iron oxide particles on the surface of biological carbon material through a self-assembly method to form a magnetic biochar; and loading the photosynthetic bacteria on the surface of the magnetic biochar through a co-incubation method, so as to obtain the magnetic biochar loaded photosynthetic bacteria material. The magnetic biochar loaded photosynthetic bacteria material is co-incubated with sewage for a period of time, so as to realize degradation of COD, ammonia nitrogen and phosphate radical in the sewage. The invention employs the electrostatic binding of high specific surface of the nano magnetic iron oxide and the bacteria with charge on the surface to achieve immobilization of strains, and magnetic iron oxide material has activation on strain enzyme, thereby enhancing the degradation of COD, ammonia nitrogen and phosphate radical by microbes.

The invention relates to a preparation method, a detection method and application of a probe drug composition for determination of metabolic activity of cytochrome P450. The composition mainly comprises a preparation made with a specific probe with major isoforms of CYP450, i.e. CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4, as an active component. Cocktail probe drug solution is prepared, the probe drug composition is injected into an animal or liver microsomes for in vitro co-incubation, and the concentration of each probe drug is determined to assess the metabolic activity of the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4. In the early stage of research and development of new drugs, the effects of the drugs on the activity of each isoform of the cytochrome P450 are screened in a high-throughput way, and the interactions of the drugs can be predicted. In the stage of clinical research, the testing can be performed with the probe drug composition in an in-vivo probe method, and the effects of the drugs on the in-vivo metabolic activity of different isoforms of the human liver CYP450 can be examined.

The invention belongs to the field of nano-particles, and particularly relates to a method for detecting alkaline phosphatase activity by molybdenum disulfide quantum dot inner-filter effect fluorescence. The method includes the steps: firstly, preparing fluorescent molybdenum disulfide quantum dots: taking molybdenum disulfide powder as a raw material, taking ethyl alcohol/water as a solvent, taking inorganic base as a stripping auxiliary and synthesizing the molybdenum disulfide quantum dots by an ultrasonic method; secondly, adding alkaline phosphatase solution into 4-nitrophenyl phosphatedisodium salt (PNNP) and magnesium sulfate alkaline buffer solution, and performing co-incubation; thirdly, adding the alkaline buffer solution into molybdenum disulfide quantum dot solution and performing further co-incubation; fourthly, building a standard work curve for detecting alkaline phosphatase; fifthly, acquiring the activity of the alkaline phosphatase in the solution to be detected according to a standard curve equation. The fluorescent molybdenum disulfide quantum dots have the advantages of stable performance, simple synthesis conditions, low price and the like, and are simple indetection process and high in selectivity and sensitivity when being used for detecting the alkaline phosphatase.

The invention discloses a method for building medicine transport models for research on BCRP (breast cancer resistance proteins) mediation for 3D (three-dimensional) organs of the small intestines of mice. The method includes separating crypts from the small intestines of the mice by means of digestion, suspending the crypts in matrigel and then joining the crypts with cell culture plates and promoting differentiation of the crypts by the aid of ADMEM/F12 media with Respondin-1, m-noggin and m-EGF cell differentiation growth factors to form the 3D organs; carrying out morphologic observation and detecting the expression level of BCRP genes and proteins to verify the feasibility of model theories; carrying out research on the trans-membrane transport activity of BCRP in the 3D organs by the aid of fluorescent substrates Hoechst 33342 of the BCRP and inhibitors Ko143 or YHO-13177 of the fluorescent substrates by co-incubation processes. The method has the advantages that the medicine trans-cell-membrane transport in-vitro models for the research on the BCRP mediation for the 3D organs of the small intestines of the mice are built for the first time, and the method for building the models is easy and convenient to implement and high in detection efficiency and speed and can be widely applied to screening BCRP substrates and inhibitors in an in-vitro manner.

The invention belongs to the technical field of chemical and biochemical medicines, particularly relates to a DNA fixed nano hydrogel microsphere, a preparation method of the DNA fixed nano hydrogel microsphere and a nucleic acid aptamer compound and an application of the DNA fixed nano hydrogel microsphere as a tumor targeting preparation. The preparation method is simple, only a segment of single-stranded DNA is synthesized at one end of the nucleic acid aptamer as a connecting arm when the nucleic acid aptamer is synthesized, and the sequence of the DNA connecting arm and the DNA sequence on the surface of the nano material of the nano hydrogel microsphere can be complemented and paired. One or a plurality of nucleic acid can be matched and connected on the surface of the nano materialat one time by co-incubation in aqueous solution so as to obtain the drug delivery carrier with the specific targeting function. According to the method, one or more nucleic acid aptamers can be connected on the surface of the drug delivery carrier at one time in a base complementary pairing mode; the base complementary pairing can be carried out in aqueous solution; reaction conditions are mild and easy to control; and the preparation process is very simple.

The invention discloses a method of utilizing an aptamer molecular switch to detect aflatoxin B1. At first, protection of an aptamer is claimed, and the sequence of the aptamer is represented by the sequence 1 in the sequence table. Then protection of a probe is claim. The probe is obtained by labeling a fluorescent group (FAM) on the 5' terminal of a single chain DNA molecule and labeling a quenching group (BHQ1) on the 3' terminal of the single chain DNA molecule. Protection of a method for detecting aflatoxin B1 is also claimed. The method comprises a step of co-incubating any one of abovementioned probes with a sample to be tested, and if the fluorescent strength is reduced after co-incubation, the sample contains aflatoxin B1. The method has the advantages that aptamer is taken as an affinity ligand and is used to detect aflatoxin B1, the advantages of aptamer can be fully exerted; the provided aptamer molecular switch can generate respond of fluorescence reduction, and the rapid and sensitive detection of aflatoxin B1 is realized therefore.

The invention discloses a method capable of rapidly, simply, conveniently and quantitatively detecting minimal inhibitory concentration, and the method comprises the following steps of: in accordance with the standard of CLSI (Clinical and Laboratory Standards Institute) (Version 2010), adding a fresh enterococcus suspension of a certain concentration into a sterile 96-well plate containing concentration gradient antibacterials for co-incubation; upon the ending of the 4-hour incubation, adding a fixed amount of fluorescent dyes SYTOX Green and DAPI (4,6-diamino-2-phenyl indole) to all the wells, protecting the wells from light for 15 minutes at room temperature, reading the fluorescent intensity of the two dyes in the wells by use of a fluorescent microplate reader respectively; after relevant background fluorescence is deducted, drawing a corresponding curve between bacterial fluorescence intensity ratio (Pdead/livel) and concentration of drug (CDrug), and determining the minimal concentration of drug corresponding to the moment the Pdead/livel is no longer fluctuated as the MIC (Minimal Inhibitory Concentration) of the antibiotic to the bacterium. The detection method provided by the invention has the characteristics of being simple, convenient, rapid and objective and being capable of performing mathematic statistics and analysis directly on detected data, becomes a new detection method for determining the minimal inhibitory concentration of antibacterials, and has a wide application prospect.

Co-incubation of an amyloid protein with sulfated macromolecules as a method for the formation of amyloid plaques. The amyloid protein may be the beta-amyloid protein or the prion protein or the like. Amyoid plaque formation in one embodiment proceeds in vitro and desireably produces amyloid plaques that stain with Congo red and demonstrate a maltese-cross pattern when viewed under polarized light. The method also produces amyloid plaques that demonstrate an "amyloid star" appearance when viewed by transmission electron microscopy. Sulfated macromolecules include a sulfated proteoglycan selected from the group consisting of perlecan, ~220 kilodalton heparan sulfate proteoglyean, glypican, cerebroglycan, aggrecan, synaptoglycan (SV2PG), syndecan, N-syndecan (also known as syndecan-3), syndecan-1, syndecan-4, neurocan, phosphacan, decorin, biglycan, versican, amphiglycan, lumican, PG-M, PG-M (3), agrin, betaglycan, claustrin, brevican, appican, epican, neuroglycan-C, and fragments thereof. Thw sulfated macromolecule may be a sulfated glycosaminoglycan selected from the group consisting of heparin, heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate, and fragments thereof. An in vivo assay is also presented for selecting a candidate therapeutic agent for inhibiting or disrupting amyloid plaque deposition or persistence. The assay includes a) pre-forming congophilic maltese-cross amyloid plaques in vitro following incubation of an amyloid protein and a selected sulfated macromolecule, b) using a first cannula and osmotic pump to continuously infuse for a selected duration the pre-formed congophilic maltese-cross amyloid plaques into a tissue or organ, c) changing the first cannulae and osmotic pump with a second cannulae and osmotic pump to administer the candidate therapeutic, and d) detecting the candidate therapeutic's ability to disrupt, reduce, or eliminate congophilic maltese-cross amyloid plaque deposition/persistence in the tissue or organ.

The invention discloses a preparation method of a three-dimensional graphene based proportional signal amplification aptasensor. The method adopts a gold nano-three-dimensional graphene compound as the modified electrode substrate material, then grafts ferrocene-labeled mucin aptamer to gold nanoparticles on a three-dimensional graphene surface, and employs bovine serum albumin to close non-specific sites on a sensing interface, and when the ferrocene-labeled aptamer captures mucin to an electrode surface, a methyl blue labeled mucin aptamer-gold nano compound is employed for co-incubation, thus obtaining the aptasensor for electrochemical detection. According to the invention, the aptamer is employed to construct a sensing interface, and is conducive to enhancing the stability and selectivity of the sensor; at the same time, the two electroactive substances ferrocene and methyl blue are introduced into the sensing system to play an internal reference role and a signal amplification role respectively. The construction method of the proportional signal amplification aptasensor has the advantages of high sensitivity, good stability, simple method, high cost-effectiveness, etc.

The invention discloses a method for detecting aflatoxin B1 by enzyme-labeled aptamer. The method sequentially includes the steps: (1) taking a coated microporous plate, adding a sample to be detected and a specific probe for co-incubation and then washing the microporous plate; (2) detecting the aflatoxin B1 by detecting corresponding signals of the specific probe. The coated microporous plate is a microporous plate coated with aflatoxin B1-BSA conjugates, the specific probe is a compound of a first element and a second element, the first element is a substance obtained by connecting biotin to the tail end of the aptamer specifically combined with the aflatoxin B1 by the aid of triethylene glycol serving as a connecting arm, and the second element is horseradish peroxidase-labeled streptavidin. The enzyme-linked aptamer analysis method has the advantages of simplicity, rapidness and high sensitivity, a plurality of samples can be rapidly analyzed, a detection kit can be made, and the method has a great application prospect in AFB1 analysis detection.

The present application discloses a method for measuring 25-hydroxyvitamin D. The method comprises the following steps: using a first reagent and a second reagent to co-incubate with a biological sample, wherein the first reagent comprises a first magnetic micro particle and a second magnetic micro particle in an acidic buffer solution, wherein the first magnetic micro particle is coated with a streptavidin magnetic micro particle; the second magnetic micro particle is the magnetic micro particle different from the first magnetic micro particle; the second reagent comprises a 25-hydroxyvitaminD antibody marker; further adding a third reagent comprising biotinylated 25-hydroxyvitamin D for co-incubation; separating the magnetic micro particles; adding a luminescent substrate and detectingthe luminescence intensity. The method of the present invention is simultaneously applicable to detection of 25-hydroxyvitamin D in serum and plasma samples without the need of additional sample processing reagents and additional sample processing steps as well.

The invention belongs to the technical field of bioengineering, and relates to a method for promoting sheep in-vitro embryo development by using follistatin, which comprises the following steps: (1) acquiring a slaughtered sheep ovary; (2) extracting follicles for later use; (3) culturing selected oocytes in a CO2 incubator, and adding into in-vitro fertilization solution drops; (4) adding the in-vitro fertilization drops, and carrying out co-incubation with the oocytes; (5) taking out the early embryo, transferring into a 10 mu g/L follistatin in-vitro culture solution, washing 3-4 times, and culturing for 24-26 hours; and (6) taking out the embryo, washing with the in-vitro culture solution, calculating the merogenesis rate, and calculating the blastula rate after culturing for 144-168 hours. By using the follistatin to treat the early embryo subjected to sheep oocyte in-vitro fertilization, the method can obviously enhance the in-vitro embryo development blastula rate.

The invention discloses a reagent for detecting anti-platelet surface receptor-specific autoantibodies and a preparation method and application thereof. The reagent has high specificity and sensitivity. The method comprises expressing a human platelet-specific receptor membrane glycoprotein GP Ib-IX and/or GP IIb/IIIa receptor through CHO cells, carrying out co-incubation on the specific membraneglycoprotein receptor expression-positive CHO cells and serum to be detected and adding a fluorescein-labeled anti-human immunoglobulin polyclonal antibody (secondary antibody) for bonding. If there is an anti-platelet receptor-specific antibody in serum or plasma, the CHO-membrane glycoprotein specific antibody-fluorescein-labeled anti-human immunoglobulin polyclonal antibody complex structure isformed, has high CHO cell fluorescence intensity and can be used for flow cytometry or fluorescence microscope examination. The method is easy to operate, has enough specific membrane glycoprotein expression positive CHO cell sources, high specificity and sensitivity and high diagnosis efficiency and can be used for basic research and clinical examination.

The invention belongs to the field of tumor cytology, and discloses a method for tumor cell detection through porous gold nanospheres. The method comprises the following steps: (1) preparing the porous gold nanospheres; (2) carrying out co-incubation on the porous gold nanospheres and a sulfydryl-modified aptamer to prepare functionalized porous gold nanospheres; (3) binding the functionalized porous gold nanospheres with sample cells, and removing the unbound porous gold nanospheres, so that a cell sample to be detected is obtained; and (4) adding a bicarbonate solution into the cell sample to be detected, and carrying out illumination under a 808nm laser. The method for the tumor cell detection through the porous gold nanospheres has the advantages that the operation is simple, and the detection cost is low; and the adopted porous gold nanospheres can be simply prepared, achieve high light and heat stability and high biocompatibility, and can produce a high temperature under the illumination of the 808nm laser for thermal decomposition of bicarbonate, so that air pressure changes in a reaction system can be monitored to distinguish tumor cells from normal cells.

The invention discloses a secretory component vesica of a gene engineering-based aAPC (artificial Antigen Presenting Cell), as well as preparation and application of a T cell vaccine constructed by anexosome. By transfecting two kinds of eukaryotic expression plasmids of pcDNAHLA-A2 and pcDNACD80 and infecting two kinds of recombinant adenovirus carriers of AdVGag and AdV41BBL, a gene engineering-based K562A2/Gag/CD80/41BBLaAPC is constructed; then exosomes are purified in K562A2/Gag/CD80/41BBL culture supernatant through a differential superspeed centrifugal method, and electron microscopingand immunoblotting analysis can be carried out, wherein the exosomes are in co-incubation with nonspecific T cells of Con-A stimulated HLA-A2 transgenic mice through incubating, so that Gag-Texo vaccine having HLA-A-A2 limitation and Gag specificity is constructed. According to the secretory component vesica disclosed by the invention, the aAPCK562A2/Gag/CD80/41BBL vesica in unlimited source andcontinuous growth is used for replacing a DC vesica in limited source and is used for preparing an HIV-1 (Human Immunodeficiency Viru I) Gag specific T cell vaccine. A novel method for preparing the Tcell vaccine by using the gene engineering-based aAPC has important influence on development of clinic therapeutic vaccines for a patient suffering HIV-1.

The invention discloses a method for screening a kinase inhibitor by utilizing an HTRF one-step method, and belongs to the field of inhibitor screening methods. The method for screening the kinase inhibitor by utilizing the HTRF one-step method comprises the following steps: sequentially adding a compound to be detected, a kinase, a substrate and ATP into a microporous plate for co-incubation; sequentially adding an antibody coupled with a recognition substrate phosphorylation site of Donor and streptavidin coupled with biotin on a recognition substrate of Acceptor into the microporous plate;incubating at room temperature, and detecting fluorescence by using an enzyme marker reading, wherein the ratio of 665nm/ 620nm is original data; according to the method, screening the kinase inhibitor at the biochemical level can be achieved, and constructing cells is not needed, and the method is more direct and quicker.

The invention provides an attenuated salmonella typhimurium mediated eukaryocyte plasmid transfection method. According to the transfection method, based on an intracellular invasion characteristic of the attenuated salmonella typhimurium, recombinant plasmids are carried to enter eukaryocytes to realize specific protein expression. Specifically, recombinant eukaryotic expression plasmids are introduced into an attenuated salmonella typhimurium VNP20009 strain in an electric shock transformation way; then recombinant bacteria and the eukaryocytes are cultured in a co-incubation manner; and finally, the attenuated salmonella typhimurium inside and outside cells is killed by a serum culture medium containing penicillin and streptomycin, and the recombinant plasmids are released to the eukaryocytes to realize the specific protein expression. Compared with conventional calcium sulfate transfection, liposome transfection and electro-transformation, the transfection method disclosed by the invention takes viable bacteria as a bearing host of specific plasmids, so that a larger number of target vectors can be obtained by only conventional culture; and in addition, the plasmid transfection operating steps are simplified, the cost is lowered, and the transfection efficiency and the cytotoxicity are comprehensively better than those in the conventional transfection method.